

# PRECEPTORSHIP PROGRAMME

## Immuno-Oncology

**ESMO  
PRECEPTORSHIP**

**ZURICH SWITZERLAND  
26-27 JUNE 2022**

From the essentials of tumour immunology  
to clinical application.

**Chairs:**

John B.A.G. Haanen, Netherlands  
Solange Peters, Switzerland  
Rolf A. Stahel, Switzerland

# ESMO PRECEPTORSHIP PROGRAMME

## IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

**Zurich, Switzerland**  
**26-27 June 2022**

---

### CO-CHAIRS:

John B.A.G. Haanen, Netherlands  
Solange Peters, Switzerland  
Rolf A. Stahel, Switzerland

### SPEAKERS:

Teresa M. S. Amaral, Germany	Lisa M. Pickering, United Kingdom
Stéphane Champiat, France	Camillo G. Porta, Italy
Pasi A. Jänne, United States	Pedro Romero, Switzerland
Mitchell Levesque, Switzerland	Cristiana Sessa, Switzerland
Michele Maio, Italy	Elizabeth Smyth, United Kingdom
Iván Márquez-Rodas, Spain	Eric Van Cutsem, Belgium
Joana T. Mourato Lopes Ribeiro, France	Michael Weller, Switzerland
Michel Obeid, Switzerland	

---

### LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their applications in cancer medicine
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

---

### ACCREDITATION

The programme of this event has been accredited with **12 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Sunday, 26 June 2022

<b>09:00-09:10</b> 10'	<b>Welcome</b>	<b>John B.A.G. Haanen, NL</b> <b>Solange Peters, CH</b> <b>Rolf A. Stahel, CH</b>
<b>09:10-10:45</b> 95'	<b>SESSION 1</b> <b>Essentials of tumour immunology</b>	<b>Chair:</b> <b>Rolf A. Stahel, CH</b>
40'	From basic to tumour immunology for oncologists	Pedro Romero, CH
40'	From translational research to clinical application	Michele Maio, IT
15'	Discussion	Faculty
<b>10:45-11:10</b>	<b>Coffee break</b>	
<b>11:10-12:25</b> 75'	<b>SESSION 2</b> <b>Essentials in immunotherapies</b>	<b>Chair:</b> <b>John B.A.G. Haanen, NL</b>
30'	Developments in Immune Checkpoint Inhibition	Stéphane Champiat, FR
30'	Developments in adoptive T-Cell transfer	John B.A.G. Haanen, NL
15'	Discussion	Faculty
<b>12:25-13:25</b>	<b>Lunch</b>	
<b>13:25-15:00</b> 95'	<b>SESSION 3</b> <b>Clinical development</b>	<b>Chair:</b> <b>Solange Peters, CH</b>
30'	Breast cancer	Joana T. Mourato Lopes Ribeiro, FR
25'	Bladder cancer	Camillo G. Porta, IT
25'	Renal cell cancer	Lisa M. Pickering, UK
15'	Discussion	Faculty
<b>15:00-16:05</b> 65'	<b>SESSION 4</b> <b>Melanoma</b>	<b>Chair:</b> <b>Solange Peters, CH</b>
25'	Immune Checkpoints	Teresa M. S. Amaral, DE
25'	Combination therapies	Iván Márquez-Rodas, ES
15'	Discussion	Faculty
<b>16:05-16:35</b>	<b>Coffee break</b>	
<b>16:35-18:05</b> 90'	<b>SESSION 5</b> <b>Clinical development</b>	<b>Chair:</b> <b>Rolf A. Stahel, CH</b>
25'	Immunotherapy of upper Gastro-Intestinal cancers	Elizabeth Smyth, UK
25'	Immunotherapy of lower Gastro-Intestinal cancers	Eric Van Cutsem, BE
25'	Gynaecological malignancies	Cristiana Sessa, CH
15'	Discussion	Faculty
<b>18:05-18:45</b> 40'	<b>SESSION 6</b> <b>Audience cases</b>	<b>Chair:</b> <b>John B.A.G. Haanen, NL</b>
40'	Participants clinical case discussion (4x10')	Faculty
<b>19:30</b>	<b>Dinner</b>	

## Monday, 27 June 2022

<b>08:30-09:10</b> 40'	<b>SESSION 7</b> <b>Audience cases</b>	<b>Chair:</b> <b>Rolf A. Stahel, CH</b>
40'	Participants clinical case discussion (4x10')	Faculty
<b>09:10-10:40</b> 90'	<b>SESSION 8</b> <b>Lung cancer and thoracic cancer</b>	<b>Chair:</b> <b>Solange Peters, CH</b>
25'	Advanced Non-Small-Cell Lung Cancer (NSCLC)	Solange Peters, CH
25'	IO for oncogene addiction and early-stage NSCLC	Pasi A. Jänne, US
25'	SCLC and mesothelioma	Rolf A. Stahel, CH
15'	Discussion	Faculty
<b>10:40-11:10</b>	<b>Coffee break</b>	
<b>11:10-11:50</b> 40'	<b>SESSION 9</b> <b>Immunomonitoring and tumour antigens</b>	<b>Chair:</b> <b>Rolf A. Stahel, CH</b>
30'	Biomarkers for immunotherapy	Mitchell Levesque, CH
10'	Discussion	Faculty
<b>11:50-12:30</b> 40'	<b>SESSION 10</b> <b>Clinical development</b>	<b>Chair:</b> <b>Solange Peters, CH</b>
25'	Glioblastoma	Michael Weller, CH
15'	Discussion	Faculty
<b>12:30-13:05</b> 35'	<b>SESSION 11</b> <b>Trial design and management of toxicities</b>	<b>Chair:</b> <b>John B.A.G. Haanen, NL</b>
25'	Management of toxicities	Michel Obeid, CH
10'	Discussion	Faculty
<b>13:05-13:15</b> 10'	<b>General discussion and closure</b>	<b>John B.A.G. Haanen, NL</b> <b>Solange Peters, CH</b> <b>Rolf A. Stahel, CH</b>
<b>13:15-14:15</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion